You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR LOXAPINE SUCCINATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for LOXAPINE SUCCINATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00648778 ↗ Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg Completed Mylan Pharmaceuticals Phase 1 2003-01-01 The objective of this study was to investigate the bioequivalence of Mylan loxapine succinate 25 mg capsules to Watson Loxitane 25 mg capsules following a single, oral 25 mg (1 x 25 mg) dose administration under fasting conditions.
NCT02820519 ↗ Tolerability and Analgesic Efficacy of Loxapine in Patients With Refractory, Chemotherapy-induced Neuropathic Pain Terminated University of Witten/Herdecke Phase 2 2016-06-01 Loxapine is an antipsychotic drug approved for the treatment of schizophrenia in several countries including the United States. In animal studies in mice, loxapine reduced neuropathic pain. Hence, in a proof-of-principle and dose-escalating study the tolerability and analgesic efficacy of loxapine will be evaluated in patients with neuropathic pain.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LOXAPINE SUCCINATE

Condition Name

Condition Name for LOXAPINE SUCCINATE
Intervention Trials
Healthy 1
Neuropathic Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LOXAPINE SUCCINATE
Intervention Trials
Neuralgia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LOXAPINE SUCCINATE

Trials by Country

Trials by Country for LOXAPINE SUCCINATE
Location Trials
Germany 1
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for LOXAPINE SUCCINATE
Location Trials
West Virginia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LOXAPINE SUCCINATE

Clinical Trial Phase

Clinical Trial Phase for LOXAPINE SUCCINATE
Clinical Trial Phase Trials
Phase 2 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LOXAPINE SUCCINATE
Clinical Trial Phase Trials
Terminated 1
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LOXAPINE SUCCINATE

Sponsor Name

Sponsor Name for LOXAPINE SUCCINATE
Sponsor Trials
Mylan Pharmaceuticals 1
University of Witten/Herdecke 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LOXAPINE SUCCINATE
Sponsor Trials
Industry 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.